Efmoroctocog alfa

Drug Profile

Efmoroctocog alfa

Alternative Names: Antihaemophilic factor VIII (recombinant), Fc fusion protein; BIIB-031; Efraloctocog alfa; Elocta; Eloctate; Factor VIII-Fc; FVIII-Fc; Long-lasting factor VIII fusion protein; Recombinant factor VIII Fc; Recombinant factor VIII Fc fusion protein; rFVIII-Fc

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer Bioverativ; Swedish Orphan Biovitrum; Syntonix Pharmaceuticals
  • Class Blood coagulation factors; Disulfides; Immunoglobulin Fc fragments; Peptides; Recombinant fusion proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 01 Feb 2017 Biogen has separated its Haemophilia Business under a new company Bioverativ
  • 01 Feb 2017 Launched for Haemophilia A in Kuwait, Liechtenstein, Iceland (IV) before February 2016
  • 03 Dec 2016 Cumulative long-term adverse events and efficacy data from the phase III Kids A-LONG and SPIRE trials in Haemophilia A presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top